Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.
about
What is new with the beta2-agonists: issues in the management of asthma.Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.Asthma, airway biology, and allergic rhinitis in AJRCCM 2000.Histological effects of inhaled corticosteroids and ß2-agonists on laryngeal mucosa in an allergic rat model.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.A critical role for IRF5 in regulating allergic airway inflammation.Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors.The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard theraIn vitro sensitization of human bronchus by beta2-adrenergic agonists.Effect of combining salmeterol and fluticasone on the progression of airway remodeling.Repeated Stress Exaggerates Lipopolysaccharide-Induced Inflammatory Response in the Rat Spleen.Effects of budesonide/formoterol combination therapy versus budesonide alone on airway dimensions in asthma.SH2-B beta expression in alveolar macrophages in BAL fluid of asthmatic guinea pigs and its role in NGF-TrkA-mediated asthma.Effect of fluticasone and salmeterol on tracheal responsiveness to ovalbumin and lung inflammation, administrated during and after sensitization
P2860
Q33213762-19EAD018-7C6F-42C2-A665-9759F9C61D04Q33737170-50AF8402-1CED-4ED5-A891-47600644ACAEQ34102220-36FEE54C-B3A3-4D0E-A634-11840AF5F4B5Q34446626-FF0455ED-1AE4-4450-A1F2-244C34986350Q34811084-B5652077-8E7B-4DBE-ADDC-B74739DFC32BQ35627925-E0489B56-F718-4162-8EA7-5E4F9603CCA8Q37362634-238E82A5-8FEE-4CEE-AE38-CD84DD569A68Q37606969-79078297-4B21-4F83-81EC-E62E001E1AFDQ40225104-7C32428B-72D8-44AD-9D0C-FFC3532C1E76Q43120166-2113FA32-2001-4B20-89E3-1E15CDAB2921Q44176962-14CE78B1-D415-46A7-A715-500622DE1EE7Q44179176-1B906896-ED06-4B16-BAD4-35862B98E362Q48015706-E67A8ADA-EDF8-4DA4-A31A-F832450F91F2Q48496612-B5B740A0-90D3-4CEB-A855-10019CF1E79FQ54773906-61D176DD-198A-4564-9AA5-17AE264697F6Q57097380-48855043-5311-42C0-99A1-70314320C46A
P2860
Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Interactions between corticost ...... progression, and exacerbation.
@ast
Interactions between corticost ...... progression, and exacerbation.
@en
type
label
Interactions between corticost ...... progression, and exacerbation.
@ast
Interactions between corticost ...... progression, and exacerbation.
@en
prefLabel
Interactions between corticost ...... progression, and exacerbation.
@ast
Interactions between corticost ...... progression, and exacerbation.
@en
P2860
P1476
Interactions between corticost ...... progression, and exacerbation.
@en
P2093
Anderson GP
P2860
P304
P356
10.1164/AJRCCM.161.SUPPLEMENT_2.A1Q4-9
P407
P433
P577
2000-03-01T00:00:00Z